^
    Apply
    Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors (NCT00878423)
    Phase 1
    Astex Pharmaceuticals, Inc.
    Completed
    Last update posted :
    01/18/2020
    Initiation :
    05/01/2008
    Primary completion :
    05/01/2013
    Completion :
    03/01/2014
    HER-2
    |
    HER-2 positive
    |
    onalespib (AT13387)
    AT13387 in Adults With Refractory Solid Tumors (NCT01246102)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/05/2018
    Initiation :
    11/19/2010
    Primary completion :
    12/30/2013
    Completion :
    10/27/2017
    HSP90AA1
    |
    onalespib (AT13387)
    A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib (NCT01712217)
    Phase 1/2
    Astex Pharmaceuticals, Inc.
    Completed
    Last update posted :
    01/19/2018
    Initiation :
    10/01/2012
    Primary completion :
    12/01/2016
    Completion :
    05/16/2017
    ALK
    |
    ALK mutation
    |
    Xalkori (crizotinib) • onalespib (AT13387)
    AT13387 in Treating Patients With Refractory Solid Tumors (NCT01245218)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    10/31/2017
    Initiation :
    11/01/2010
    Primary completion :
    08/01/2011
    HER-2 • HSP90AA1
    |
    onalespib (AT13387)